Tarsus Pharmaceuticals, Inc. (TARS) is a rapidly emerging, late-stage biopharmaceutical company that focuses predominantly on the development and commercialization of novel therapeutic treatments. The company is committed to providing solutions for diseases with high unmet needs, particularly conditions related to ophthalmology. Its primary area of research and product development involves the creation of drugs aimed at effectively managing and curing conditions of the eye.
Based in California, USA, Tarsus Pharmaceuticals, Inc. was founded in 2017, by a group of experienced industry professionals with extensive background in pharmacology, ophthalmology, and drug development. These professionals came together with a shared goal to address the critical need for new treatments in ophthalmology. They recognized the need for innovative therapeutics in this field, which led to the establishment of Tarsus Pharmaceuticals.
The flagship product of the company, an investigational drug named TP-03, addresses Demodex blepharitis, an ocular condition caused due to an infestation of Demodex mites. Currently, there are no FDA-approved treatments for this largely prevalent, yet largely ignored disease. If successfully tested and approved, TP-03 could transform the therapeutic landscape for Demodex blepharitis, providing physicians with an effective treatment option and offering relief to millions of patients worldwide, who currently have limited or no options for meaningful relief.
Tarsus Pharmaceuticals, Inc. has been built on a foundation that emphasizes rigorous scientific research, a robust clinical approach, and a deep commitment to patient care. With a patient-centric approach, Tarsus is dedicated to improving the lives of people suffering from debilitating eye conditions. The company envisions creating global therapeutic solutions that will ease the sufferings caused by such health issues.
The company has registered significant growth since its inception, bolstered by its focused research and development strategies in the field of ophthalmology. This has also been recognized in financial markets, with its stock listed on the NASDAQ Global Market under the symbol "TARS".
Aside from TP-03, Tarsus Pharmaceuticals is also developing other pharmaceutical products targeting various eye diseases. Each product is designed based on careful research and proven scientific principles, and Tarsus hopes to get several of them to market in the coming years, despite the long and rigorous drug approval processes.
Through its important work, Tarsus Pharmaceuticals, Inc. underlines its commitment to addressing the unmet medical needs related to eye health. Its dynamic approach and focused strategies position the company well in the competitive biopharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Pyott David E I, a director of Tarsus Pharmaceuticals (NASDAQ: TARS), recently exercised options resulting in a holding of 9,575 shares, which represents approximately 2.1% of his total shares in the company. This transaction also accounted for about 24.9% of his previous derivative securities holdings. The option exercise took place on September 15, 2026.
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals for an initial payment of $270 million in cash and 2,908,692 shares of Tarsus common stock. The deal also includes potential milestone payments of up to $350 million tied to regulatory approval and the first U.S. sale of an Alkeus product, along with tiered revenue sharing. Alkeus will continue to operate as a wholly-owned subsidiary of Tarsus.
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, adding ALK-001, an investigational oral therapy for Stargardt disease, to its pipeline. This acquisition aims to strengthen Tarsus's position in eyecare, particularly with ALK-001's potential to treat a condition with no FDA-approved therapies, and topline data for its phase 3 trial expected in 2029. The deal involved an upfront payment of $450 million and potential milestones up to $350 million.
Tarsus Pharmaceuticals has acquired Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), an investigational drug for Stargardt disease. This acquisition expands Tarsus's ophthalmology portfolio, leveraging its existing infrastructure in eye care. The value of the deal hinges on the Phase 3 clinical trial readout for gildeuretinol, which targets the underlying biology of the disease.
Tarsus Pharmaceuticals' shares increased after the company completed its acquisition of Alkeus Pharmaceuticals. The acquisition, initially announced in early August, is valued at approximately $800 million. Tarsus Pharmaceuticals is a biopharmaceutical company specializing in eye care, with its lead product XDEMVY targeting Demodex blepharitis.